Alexander W. Hird, Ph.D.

Affiliations: 
2006 Boston College, Newton, MA, United States 
Area:
catalysts
Google:
"Alexander Hird"
Mean distance: 8.07
 
SNBCP

Parents

Sign in to add mentor
Amir H. Hoveyda grad student 2006 Boston College
 (New methods for catalytic enantioselective conjugate addition of dialkylzinc reagents to alpha,beta-unsaturated carbonyls: Discovery and use of new catalysts.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Maia de Oliveira T, Korboukh V, Caswell S, et al. (2020) The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif. The Biochemical Journal. 477: 275-284
Yang B, Hird AW, Bodnarchuk MS, et al. (2019) Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254). Bioorganic & Medicinal Chemistry. 115227
Balazs AYS, Carbajo RJ, Davies NL, et al. (2019) Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles. Journal of Medicinal Chemistry
Hird AW, Tron AE. (2019) Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacology & Therapeutics
Tron AE, Belmonte MA, Adam A, et al. (2018) Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341
Yang B, Vasbinder M, Hird AW, et al. (2018) Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. Journal of Medicinal Chemistry
Tron AE, Belmonte MA, Criscione S, et al. (2018) Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia Cancer Research. 78: 302-302
Barlaam B, Savi CD, Drew L, et al. (2018) Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies Cancer Research. 78: 1650-1650
Johannes JW, Bates S, Beigie C, et al. (2017) Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors". Acs Medicinal Chemistry Letters. 8: 1204
Johannes JW, Bates S, Beigie C, et al. (2017) Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. Acs Medicinal Chemistry Letters. 8: 239-244
See more...